- Home
- BRKL vs WVE Comparison
BRKL vs WVE Comparison
Compare BRKL & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKL
- WVE
- Stock Information
- Founded
- BRKL 1871
- WVE 2012
- Country
- BRKL United States
- WVE Singapore
- Employees
- BRKL N/A
- WVE N/A
- Industry
- BRKL Savings Institutions
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- BRKL Finance
- WVE Health Care
- Exchange
- BRKL Nasdaq
- WVE Nasdaq
- Market Cap
- BRKL 897.3M
- WVE 939.3M
- IPO Year
- BRKL 1998
- WVE 2015
- Fundamental
- Price
- BRKL $11.00
- WVE $6.27
- Analyst Decision
- BRKL Buy
- WVE Strong Buy
- Analyst Count
- BRKL 2
- WVE 11
- Target Price
- BRKL $15.25
- WVE $20.91
- AVG Volume (30 Days)
- BRKL 489.3K
- WVE 1.8M
- Earning Date
- BRKL 04-23-2025
- WVE 05-08-2025
- Dividend Yield
- BRKL 4.87%
- WVE N/A
- EPS Growth
- BRKL N/A
- WVE N/A
- EPS
- BRKL 0.82
- WVE N/A
- Revenue
- BRKL $338,567,000.00
- WVE $104,939,000.00
- Revenue This Year
- BRKL $55.27
- WVE N/A
- Revenue Next Year
- BRKL $37.40
- WVE N/A
- P/E Ratio
- BRKL $13.39
- WVE N/A
- Revenue Growth
- BRKL N/A
- WVE N/A
- 52 Week Low
- BRKL $8.01
- WVE $4.25
- 52 Week High
- BRKL $13.15
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- BRKL 60.67
- WVE 40.37
- Support Level
- BRKL $10.50
- WVE $6.23
- Resistance Level
- BRKL $11.17
- WVE $7.07
- Average True Range (ATR)
- BRKL 0.22
- WVE 0.59
- MACD
- BRKL 0.10
- WVE 0.01
- Stochastic Oscillator
- BRKL 85.92
- WVE 26.35
About BRKL Brookline Bancorp Inc.
Brookline Bancorp Inc operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.